Resource Center

More to Explore - Information About Blood Cancers for Patients, Families and Healthcare Professionals

The Word:


January 14, 2014 - Acute Lymphoblastic Leukemia (ALL): Understanding Diagnosis & Treatment for Adults

Your order contains  item(s)  View Order

Note: The free Adobe Acrobat Reader® is required to view and print Adobe PDF files, and the free Windows Media Player or RealPlayer is required to listen to the MP3 audio files.

Date: January 14, 2014
Time: 1:00 p.m. - 2:30 p.m. ET
Location: Telephone/Web
View: Program Slides | Program Slides (Spanish)
Read: Transcript | Transcript (Spanish)
Listen: Presentation | Q&A Session | Presentation (Spanish) | Q&A Session (Spanish)
Access: Virtual Lecture

Topics Covered

  • How acute lymphoblastic leukemia (ALL) is diagnosed
  • The importance of risk assessment when developing a treatment plan
  • Current and emerging treatment options
  • The role of clinical trials in the continuing improvement of treatment options
  • Maintaining open communication with your treatment team


Dan Douer, MD
Attending Physician
Leukemia Service
Memorial Sloan-Kettering Cancer Center
New York, NY

Questions Asked by the Adult ALL Community

  • Doctor, you refer to event free survival- What is considered an event, and who is included in a five-year, event free survival?
  • Can Ph+ (Philadelphia chromosome positive) ALL be healed completely?  Do I have to take a TKI medication like Gleevec® for the rest of my life?
  • What are the side effects of administering intrathecal methotrexate?
  • Please talk about adult maintenance protocols.  How long is the maintenance protocol?
  • Would haploidentical transplants (half-matched donor transplants) be appropriate for adults?
  • Is AVN (avascular necrosis) a common side effect of ALL treatment?
  • Is radiation treatment appropriate for ALL patients?
  • Since blood counts rise and fall while you are on maintenance, how would you know if you are relapsing?
  • Can you determine how long one had leukemia prior to diagnosis?
  • What is being done to minimize long-term and late effects such as cardiac function and neuropathy for patients with ALL?
  • What are the advantages and disadvantages of clinical trials for adult ALL patients?
  • Is it possible to be considered cancer-free, or will patients have to be tested for relapse for the rest of their lives?
  • How important is MRD (minimal residual disease)?
  • Is transplantation the only option for a relapsed adult ALL patient?

Sponsors and Supporters

This program is presented by The Leukemia & Lymphoma Society and sponsored by Amgen.

last updated on Thursday, March 19, 2015